Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

The Future of the GLP-1 Receptor Agonists

The Future of the GLP-1 Receptor Agonists Opinion EDITORIAL Irl B. Hirsch, MD The discovery of the enteric hormone glucagon-like peptide 1 mortality in patients with diabetes, this may be the ultimate (GLP-1), and subsequent demonstration that its physiologic ac- treatment benefit of these agents. tions to lower blood glucose levels can be extended to the treat- The cardiovascular benefit of several GLP-1RAs has led to changes in treatment recommendations for type 2 diabetes. ment of type 2 diabetes, have been important therapeutic 1,2 advances. The approval of The American Diabetes Association (ADA) and the European exenatide for clinical use in Association for the Study of Diabetes now suggest adding a Related article page 1466 the United States and Europe GLP-1RA with proven cardiovascular benefit to metformin for in 2005 was the first of several GLP-1 receptor agonists individuals with proven atherosclerotic cardiovascular dis- (GLP-1RAs) to advance the clinical use of the dual effects of these ease who need further glycemic lowering. Given the benefi- drugs to lower glycated hemoglobin (HbA ) and reduce body cial effect of these agents on obesity, they are also suggested 1c weight. This introduced a new and needed option to treat pa- therapy after metformin because of their potential to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

The Future of the GLP-1 Receptor Agonists

JAMA , Volume 321 (15) – Apr 16, 2019

Loading next page...
 
/lp/american-medical-association/the-future-of-the-glp-1-receptor-agonists-vPjyZ04RtB
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2019.2941
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Irl B. Hirsch, MD The discovery of the enteric hormone glucagon-like peptide 1 mortality in patients with diabetes, this may be the ultimate (GLP-1), and subsequent demonstration that its physiologic ac- treatment benefit of these agents. tions to lower blood glucose levels can be extended to the treat- The cardiovascular benefit of several GLP-1RAs has led to changes in treatment recommendations for type 2 diabetes. ment of type 2 diabetes, have been important therapeutic 1,2 advances. The approval of The American Diabetes Association (ADA) and the European exenatide for clinical use in Association for the Study of Diabetes now suggest adding a Related article page 1466 the United States and Europe GLP-1RA with proven cardiovascular benefit to metformin for in 2005 was the first of several GLP-1 receptor agonists individuals with proven atherosclerotic cardiovascular dis- (GLP-1RAs) to advance the clinical use of the dual effects of these ease who need further glycemic lowering. Given the benefi- drugs to lower glycated hemoglobin (HbA ) and reduce body cial effect of these agents on obesity, they are also suggested 1c weight. This introduced a new and needed option to treat pa- therapy after metformin because of their potential to

Journal

JAMAAmerican Medical Association

Published: Apr 16, 2019

References